435 related articles for article (PubMed ID: 22490570)
1. Safety and efficacy of first-line bevacizumab combined with taxane therapy in Chinese patients with HER2-negative locally recurrent or metastatic breast cancer: findings from the ATHENA study.
Xu BH; Jiang ZF; Shen ZZ; Guan ZZ; Chen ZD; Cheng Y; Zheng H; Jiang J; Wang XJ; Tong ZS; Qin SK; Luo Y; Yao M; Wang LW; He J
Chin Med J (Engl); 2012 Mar; 125(5):764-9. PubMed ID: 22490570
[TBL] [Abstract][Full Text] [Related]
2. First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.
Smith IE; Pierga JY; Biganzoli L; Cortés-Funes H; Thomssen C; Pivot X; Fabi A; Xu B; Stroyakovskiy D; Franke FA; Kaufman B; Mainwaring P; Pienkowski T; De Valk B; Kwong A; González-Trujillo JL; Koza I; Petrakova K; Pereira D; Pritchard KI;
Ann Oncol; 2011 Mar; 22(3):595-602. PubMed ID: 20819780
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.
Thuss-Patience PC; Shah MA; Ohtsu A; Van Cutsem E; Ajani JA; Castro H; Mansoor W; Chung HC; Bodoky G; Shitara K; Phillips GDL; van der Horst T; Harle-Yge ML; Althaus BL; Kang YK
Lancet Oncol; 2017 May; 18(5):640-653. PubMed ID: 28343975
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
von Minckwitz G; Puglisi F; Cortes J; Vrdoljak E; Marschner N; Zielinski C; Villanueva C; Romieu G; Lang I; Ciruelos E; De Laurentiis M; Veyret C; de Ducla S; Freudensprung U; Srock S; Gligorov J
Lancet Oncol; 2014 Oct; 15(11):1269-78. PubMed ID: 25273342
[TBL] [Abstract][Full Text] [Related]
5. First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study.
Aogi K; Masuda N; Ohno S; Oda T; Iwata H; Kashiwaba M; Fujiwara Y; Kamigaki S; Ito Y; Ueno T; Takashima S
Breast Cancer Res Treat; 2011 Oct; 129(3):829-38. PubMed ID: 21805309
[TBL] [Abstract][Full Text] [Related]
6. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO.
Pivot X; Schneeweiss A; Verma S; Thomssen C; Passos-Coelho JL; Benedetti G; Ciruelos E; von Moos R; Chang HT; Duenne AA; Miles DW
Eur J Cancer; 2011 Nov; 47(16):2387-95. PubMed ID: 21757334
[TBL] [Abstract][Full Text] [Related]
8. Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy.
Kim JW; Kim JH; Im SA; Lee KH; Kim JS; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1023-9. PubMed ID: 24036907
[TBL] [Abstract][Full Text] [Related]
9. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
Bachelot T; Ciruelos E; Schneeweiss A; Puglisi F; Peretz-Yablonski T; Bondarenko I; Paluch-Shimon S; Wardley A; Merot JL; du Toit Y; Easton V; Lindegger N; Miles D;
Ann Oncol; 2019 May; 30(5):766-773. PubMed ID: 30796821
[TBL] [Abstract][Full Text] [Related]
10. [Bevacizumab and taxanes in the first-line treatment of metastatic breast cancer : overall survival and subgroup analyses of the ATHENA study in France].
Pierga JY; Delva R; Pivot X; Espié M; Dalenc F; Serin D; Veyret C; Lortholary A; Gligorov J; Joly K; Hernandez J; Hardy-Bessard AC
Bull Cancer; 2014 Sep; 101(9):780-8. PubMed ID: 25295737
[TBL] [Abstract][Full Text] [Related]
11. Final overall survival results and effect of prolonged (≥ 1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial.
Smith I; Pierga JY; Biganzoli L; Cortes-Funes H; Thomssen C; Saracchini S; Nisenbaum B; Pelaez I; Duenne AA; Pritchard KI
Breast Cancer Res Treat; 2011 Nov; 130(1):133-43. PubMed ID: 21830015
[TBL] [Abstract][Full Text] [Related]
12. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.
Gligorov J; Doval D; Bines J; Alba E; Cortes P; Pierga JY; Gupta V; Costa R; Srock S; de Ducla S; Freudensprung U; Mustacchi G
Lancet Oncol; 2014 Nov; 15(12):1351-60. PubMed ID: 25273343
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01).
Hurvitz SA; Allen HJ; Moroose RL; Chan D; Hagenstad C; Applebaum SH; Patel G; Hu EH; Ryba N; Lin LS; Wang H; Glaspy J; Slamon DJ; Kabbinavar F
Clin Breast Cancer; 2010 Aug; 10(4):307-12. PubMed ID: 20705564
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.
Lam SW; de Groot SM; Honkoop AH; Jager A; ten Tije AJ; Bos MM; Linn SC; van den Bosch J; Kroep JR; Braun JJ; van Tinteren H; Boven E;
Eur J Cancer; 2014 Dec; 50(18):3077-88. PubMed ID: 25459393
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer.
Rodgers M; Soares M; Epstein D; Yang H; Fox D; Eastwood A
Health Technol Assess; 2011 May; 15 Suppl 1():1-12. PubMed ID: 21609648
[TBL] [Abstract][Full Text] [Related]
16. First-line bevacizumab-containing therapy for triple-negative breast cancer: analysis of 585 patients treated in the ATHENA study.
Thomssen C; Pierga JY; Pritchard KI; Biganzoli L; Cortes-Funes H; Petráková K; Kaufman B; Duenne A; Smith I
Oncology; 2012; 82(4):218-27. PubMed ID: 22508241
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
Lang I; Brodowicz T; Ryvo L; Kahan Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Messinger D; Zielinski C;
Lancet Oncol; 2013 Feb; 14(2):125-33. PubMed ID: 23312888
[TBL] [Abstract][Full Text] [Related]
18. Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.
Ortega V; Antón A; Garau I; Afonso N; Calvo L; Fernández Y; Martínez-García M; Blanco E; Zamora P; García M; Illarramendi JJ; Rodríguez Sánchez CA; Sampayo M; Aguirre E; Pérez-García JM; Cortés J; Llombart-Cussac A
Clin Breast Cancer; 2019 Apr; 19(2):105-112. PubMed ID: 30679100
[TBL] [Abstract][Full Text] [Related]
19. HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.
Kim JW; Kim JH; Im SA; Kim YJ; Han HS; Kim JS; Lee KH; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
Cancer Chemother Pharmacol; 2013 Jul; 72(1):109-15. PubMed ID: 23673443
[TBL] [Abstract][Full Text] [Related]
20. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer.
Vrdoljak E; Marschner N; Zielinski C; Gligorov J; Cortes J; Puglisi F; Aapro M; Fallowfield L; Fontana A; Inbar M; Kahan Z; Welt A; Lévy C; Brain E; Pivot X; Putzu C; González Martín A; de Ducla S; Easton V; von Minckwitz G
Ann Oncol; 2016 Nov; 27(11):2046-2052. PubMed ID: 27502725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
